Thumbnail - Request a copy

Estimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective

Lévy, Pierre; Smadja, David M.; Dorey, Julie; Toumi, Mondher; Meinecke, Anna-Katharina; Bowrin, Kevin; Briere, Jean-Baptiste (2019), Estimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective, Journal of Market Access & Health Policy, 7, 1. 10.1080/20016689.2018.1564506

Type
Article accepté pour publication ou publié
Date
2019
Journal name
Journal of Market Access & Health Policy
Volume
7
Number
1
Publisher
Taylor & Francis
Publication identifier
Metadata
Show full item record
Author(s)
Lévy, Pierre
Laboratoire d'Economie de Dauphine [LEDa]
Smadja, David M. cc
INSERM, l'Institut national de la santé et de la recherche médicale [INSERM]
Dorey, Julie

Toumi, Mondher
Laboratoire de Santé Publique
Pharmaco-Epidémiologie
Centre d'études et de recherche sur les services de santé et la qualité de vie [CEReSS]
Meinecke, Anna-Katharina

Bowrin, Kevin

Briere, Jean-Baptiste
Subjects / Keywords
Nonvalvular atrial fibrillation; vitamin K antagonists; international normalised ratio; monitoring; resource use and costs; real-world research; France
JEL
I12 - Health Behavior
I11 - Analysis of Health Care Markets